ExodusPoint Capital Management LP lowered its position in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,521 shares of the company’s stock after selling 41,908 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Editas Medicine were worth $557,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Covestor Ltd increased its holdings in shares of Editas Medicine by 9,693.3% in the first quarter. Covestor Ltd now owns 1,469 shares of the company’s stock valued at $28,000 after purchasing an additional 1,454 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Editas Medicine in the second quarter valued at approximately $32,000. Quantbot Technologies LP acquired a new position in shares of Editas Medicine in the first quarter valued at approximately $44,000. Great West Life Assurance Co. Can acquired a new position in shares of Editas Medicine in the third quarter valued at approximately $48,000. Finally, Federated Hermes Inc. acquired a new position in shares of Editas Medicine in the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 69.67% of the company’s stock.
In other news, EVP Mark S. Shearman sold 2,790 shares of the company’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $9.67, for a total value of $26,979.30. Following the sale, the executive vice president now directly owns 65,559 shares in the company, valued at $633,955.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Mark S. Shearman sold 2,790 shares of the stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $9.67, for a total transaction of $26,979.30. Following the transaction, the executive vice president now directly owns 65,559 shares in the company, valued at $633,955.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michelle Robertson sold 4,287 shares of the stock in a transaction dated Monday, February 13th. The stock was sold at an average price of $9.67, for a total value of $41,455.29. Following the transaction, the chief financial officer now owns 76,243 shares in the company, valued at $737,269.81. The disclosure for this sale can be found here. Insiders have sold 9,175 shares of company stock worth $86,572 over the last three months. 1.30% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Editas Medicine Stock Performance
EDIT opened at $9.04 on Tuesday. The business’s fifty day moving average is $9.28 and its two-hundred day moving average is $11.57. The company has a market cap of $623.49 million, a price-to-earnings ratio of -2.82 and a beta of 1.87. Editas Medicine, Inc. has a one year low of $7.70 and a one year high of $21.59.
Editas Medicine (NASDAQ:EDIT – Get Rating) last issued its quarterly earnings data on Wednesday, February 22nd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.04). Editas Medicine had a negative net margin of 1,118.32% and a negative return on equity of 50.28%. The company had revenue of $6.54 million during the quarter, compared to analysts’ expectations of $3.76 million. During the same quarter in the prior year, the company earned ($0.61) earnings per share. The firm’s revenue was down 47.6% compared to the same quarter last year. On average, analysts predict that Editas Medicine, Inc. will post -3.03 EPS for the current fiscal year.
Editas Medicine Profile
Editas Medicine, Inc engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J.
- Get a free copy of the StockNews.com research report on Editas Medicine (EDIT)
- Reserve Your Spot With These Hotels The Analysts Support
- Cruise Line Stocks Still Have Some Choppy Waters to Navigate
- Four Vegan Food Stocks Performing Beyond the Norm
- Ocean Interest Electrifies Fisker Stock
- Is Freshpet Ready For A Fresh Rally?
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating).
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.